BioAtla (BCAB) Stock Price, News & Analysis

Company Overview

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $0.48 to $0.50
• 50-Day Range: $0.48 to $2.37
• 52-Week Range: $0.45 to $4.02
• Volume: 373,650 shs
• Average Volume: 1.49 million shs
• Market Capitalization: $23.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Moderate Buy

BioAtla Stock Analysis - MarketRank™

BioAtla scored higher than 54% of companies evaluated by MarketBeat, and ranked 564th out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

BioAtla has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

BioAtla has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioAtla are expected to grow in the coming year, from ($1.46) to ($1.40) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioAtla is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioAtla is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioAtla has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.10% of the outstanding shares of BioAtla have been sold short.

Short Interest Ratio / Days to Cover

BioAtla has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioAtla has recently increased by 11.39%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioAtla does not currently pay a dividend.

Dividend Growth

BioAtla does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.10% of the outstanding shares of BioAtla have been sold short.

Short Interest Ratio / Days to Cover

BioAtla has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioAtla has recently increased by 11.39%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: N/A

News Sentiment

BioAtla has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for BioAtla this week, compared to 1 article on an average week.

Search Interest

8 people have searched for BCAB on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioAtla insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.50% of the stock of BioAtla is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

77.23% of the stock of BioAtla is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BCAB Stock Analysis - Frequently Asked Questions

How have BCAB shares performed this year?

BioAtla's stock was trading at $0.5912 at the start of the year. Since then, BCAB shares have decreased by 16.6% and is now trading at $0.4930.
View the best growth stocks for 2025 here.

How were BioAtla's earnings last quarter?

BioAtla, Inc. (NASDAQ:BCAB) released its quarterly earnings results on Thursday, November, 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.34) by $0.12. The firm earned $11 million during the quarter.

When did BioAtla IPO?

BioAtla (BCAB) raised $150 million in an initial public offering (IPO) on Wednesday, December 16th 2020. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG acted as the underwriters for the IPO.

Who are BioAtla's major shareholders?

Top institutional investors of BioAtla include Magnus Financial Group LLC (0.10%). Insiders that own company stock include Jay M Phd Short, Christian Vasquez, Lawrence Steinman and Sylvia Mcbrinn.
View institutional ownership trends.

How do I buy shares of BioAtla?

Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of BioAtla own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioAtla investors own include NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Visa (V).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 1/17/2025
• Next Earnings (Estimated): 3/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BCAB
• CUSIP: N/A
• CIK: 1826892
• Web: www.bioatla.com
• Phone: 858-558-0708
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.00
• High Stock Price Target: $7.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +1,127.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-123,460,000.00
• Net Margins: N/A
• Pretax Margin: -743.79%
• Return on Equity: -187.30%
• Return on Assets: -96.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.11
• Quick Ratio: 3.11

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.47 per share
• Price / Book: 0.33

Miscellaneous

• Outstanding Shares: 48,350,000
• Free Float: 42,786,000
• Market Cap: $23.64 million
• Optionable: Optionable
• Beta: 1.17